Plasma with NOAC – Fondaparinux (Arixtra®)

Frozen

Packaging options

6-PPFOND	Vial	1 x 1.0 mL

Description of the Plasma with NOAC – Fondaparinux (Arixtra®)

Advantages

Minimize test time. Ready to use.

Informations

Arixtra is obtained by chemical synthesis. It is an injectable anticoagulant that selectively inhibits FXa. In low doses it is used in the preventive treatment of venous thromboembolic accidents and in high doses it is used in the treatment of venous thrombosis.

product sheet

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

My personal Space

Nouveau client

Plasma with NOAC – Fondaparinux (Arixtra®)

Price list, safety data sheets and notices are accessible to our registered customers.

My personal Space

Nouveau client

Plasma with NOAC – Fondaparinux (Arixtra®)

Price list, safety data sheets and notices are accessible to our registered customers.

Associated products

Anticoagulant plasma – DTI – Argatroban – U/mL

Anticoagulant plasma – DTI – bivalirudin – U/mL

Plasma with direct thrombin inhibitor (Lepirudin)

Plasma with low molecular weight heparin (Fragmin)

Plasma with low molecular weight heparin (Innohep)

Plasma with low molecular weight heparin (Lovenox)

Plasma with oral anticoagulant – INR 3.00–3.99

Plasma with oral anticoagulant plasma - INR ≥ 4.00

Plasma with oral anticoagulant plasma – INR < 2.00

Plasma with oral anticoagulant plasma – INR 2.00-2.99